Lycopene intervention reduces inflammation and improves HDL functionality in moderately overweight middle-aged individuals

Jane McEneny (Corresponding Author), Lauren Wade , Ian S Young, Lindsey Masson, Garry Duthie, Ann McGinty, C McMaster, Frank Thies

Research output: Contribution to journalArticle

55 Citations (Scopus)

Abstract

The management of overweight subjects by interventions aimed at reducing inflammation is highly desirable. To date, observational studies have identified a link between increased dietary antioxidant intake and reduced cardiovascular morbidity. However, direct trial evidence regarding the ability of antioxidants to influence inflammation is lacking. Therefore, this study examined lycopene's ability to lower systemic and high-density lipoprotein (HDL)-associated inflammation in moderately overweight middle-aged subjects. Serum was collected before and after a 12-week intervention from 54 moderately overweight, middle-aged individuals. Subjects were randomised to one of three groups: control diet (<10 mg lycopene/week), lycopene-rich diet (224-350 mg lycopene/week) and lycopene supplement (70 mg lycopene/week). HDL was subfractionated into HDL(2&3) by rapid ultracentrifugation. Compliance was monitored by assessing lycopene concentration in serum and HDL(2&3). Systemic and HDL-associated inflammation was assessed by measuring serum amyloid A (SAA) levels. HDL functionality was determined by monitoring the activities of paraoxonase-1 (PON-1), cholesteryl ester transfer protein (CETP) and lecithin cholesterol acyltransferase (LCAT). Lycopene increased in serum and HDL(2&3) following both lycopene interventions (P<.001, for all), while SAA decreased in serum following the lycopene supplement and in HDL(3) following both lycopene interventions (P<.05 for all). PON-1 activity increased in serum and HDL(2&3) in both lycopene groups (P<.05, for all). Furthermore, the activity of CETP decreased in serum following the lycopene supplement, while the activity of LCAT increased in serum and HDL(3) following both lycopene interventions (P<.05 for all). These results demonstrate that in moderately overweight, middle-aged subjects, increasing lycopene intake leads to changes to HDL(2&3), which we suggest enhanced their antiatherogenic properties. Overall, these results show the heart-protective properties of increased lycopene intake.
Original languageEnglish
Pages (from-to)163-168
Number of pages6
JournalThe Journal of Nutritional Biochemistry
Volume24
Issue number1
DOIs
Publication statusPublished - Jan 2013

Fingerprint

HDL Lipoproteins
Inflammation
HDL2 Lipoprotein
Serum
HDL3 Lipoprotein
Cholesterol Ester Transfer Proteins
Phosphatidylcholine-Sterol O-Acyltransferase
Aryldialkylphosphatase
Serum Amyloid A Protein
lycopene
Nutrition
Antioxidants
Diet
Ultracentrifugation
Compliance
Observational Studies

Keywords

  • apolipoprotein A-I
  • aryldialkylphosphatase
  • carotenoids
  • cholesterol ester transfer proteins
  • humans
  • lipoproteins, HDL
  • middle aged
  • overweight
  • phosphatidylcholine-sterol o-acyltransferase
  • serum amyloid A protein
  • lycopene
  • HDL2&3 functionality
  • inflammation
  • serum amyloid A
  • HDL-associated enzymes

Cite this

Lycopene intervention reduces inflammation and improves HDL functionality in moderately overweight middle-aged individuals. / McEneny, Jane (Corresponding Author); Wade , Lauren; Young, Ian S; Masson, Lindsey ; Duthie, Garry; McGinty, Ann; McMaster, C; Thies, Frank.

In: The Journal of Nutritional Biochemistry, Vol. 24, No. 1, 01.2013, p. 163-168.

Research output: Contribution to journalArticle

McEneny, Jane ; Wade , Lauren ; Young, Ian S ; Masson, Lindsey ; Duthie, Garry ; McGinty, Ann ; McMaster, C ; Thies, Frank. / Lycopene intervention reduces inflammation and improves HDL functionality in moderately overweight middle-aged individuals. In: The Journal of Nutritional Biochemistry. 2013 ; Vol. 24, No. 1. pp. 163-168.
@article{d1cf33a68634404fbf1ffb6bfd350602,
title = "Lycopene intervention reduces inflammation and improves HDL functionality in moderately overweight middle-aged individuals",
abstract = "The management of overweight subjects by interventions aimed at reducing inflammation is highly desirable. To date, observational studies have identified a link between increased dietary antioxidant intake and reduced cardiovascular morbidity. However, direct trial evidence regarding the ability of antioxidants to influence inflammation is lacking. Therefore, this study examined lycopene's ability to lower systemic and high-density lipoprotein (HDL)-associated inflammation in moderately overweight middle-aged subjects. Serum was collected before and after a 12-week intervention from 54 moderately overweight, middle-aged individuals. Subjects were randomised to one of three groups: control diet (<10 mg lycopene/week), lycopene-rich diet (224-350 mg lycopene/week) and lycopene supplement (70 mg lycopene/week). HDL was subfractionated into HDL(2&3) by rapid ultracentrifugation. Compliance was monitored by assessing lycopene concentration in serum and HDL(2&3). Systemic and HDL-associated inflammation was assessed by measuring serum amyloid A (SAA) levels. HDL functionality was determined by monitoring the activities of paraoxonase-1 (PON-1), cholesteryl ester transfer protein (CETP) and lecithin cholesterol acyltransferase (LCAT). Lycopene increased in serum and HDL(2&3) following both lycopene interventions (P<.001, for all), while SAA decreased in serum following the lycopene supplement and in HDL(3) following both lycopene interventions (P<.05 for all). PON-1 activity increased in serum and HDL(2&3) in both lycopene groups (P<.05, for all). Furthermore, the activity of CETP decreased in serum following the lycopene supplement, while the activity of LCAT increased in serum and HDL(3) following both lycopene interventions (P<.05 for all). These results demonstrate that in moderately overweight, middle-aged subjects, increasing lycopene intake leads to changes to HDL(2&3), which we suggest enhanced their antiatherogenic properties. Overall, these results show the heart-protective properties of increased lycopene intake.",
keywords = "apolipoprotein A-I, aryldialkylphosphatase, carotenoids, cholesterol ester transfer proteins, humans, lipoproteins, HDL, middle aged, overweight, phosphatidylcholine-sterol o-acyltransferase, serum amyloid A protein, lycopene, HDL2&3 functionality, inflammation, serum amyloid A, HDL-associated enzymes",
author = "Jane McEneny and Lauren Wade and Young, {Ian S} and Lindsey Masson and Garry Duthie and Ann McGinty and C McMaster and Frank Thies",
year = "2013",
month = "1",
doi = "10.1016/j.jnutbio.2012.03.015",
language = "English",
volume = "24",
pages = "163--168",
journal = "The Journal of Nutritional Biochemistry",
issn = "0955-2863",
publisher = "Elsevier Inc.",
number = "1",

}

TY - JOUR

T1 - Lycopene intervention reduces inflammation and improves HDL functionality in moderately overweight middle-aged individuals

AU - McEneny, Jane

AU - Wade , Lauren

AU - Young, Ian S

AU - Masson, Lindsey

AU - Duthie, Garry

AU - McGinty, Ann

AU - McMaster, C

AU - Thies, Frank

PY - 2013/1

Y1 - 2013/1

N2 - The management of overweight subjects by interventions aimed at reducing inflammation is highly desirable. To date, observational studies have identified a link between increased dietary antioxidant intake and reduced cardiovascular morbidity. However, direct trial evidence regarding the ability of antioxidants to influence inflammation is lacking. Therefore, this study examined lycopene's ability to lower systemic and high-density lipoprotein (HDL)-associated inflammation in moderately overweight middle-aged subjects. Serum was collected before and after a 12-week intervention from 54 moderately overweight, middle-aged individuals. Subjects were randomised to one of three groups: control diet (<10 mg lycopene/week), lycopene-rich diet (224-350 mg lycopene/week) and lycopene supplement (70 mg lycopene/week). HDL was subfractionated into HDL(2&3) by rapid ultracentrifugation. Compliance was monitored by assessing lycopene concentration in serum and HDL(2&3). Systemic and HDL-associated inflammation was assessed by measuring serum amyloid A (SAA) levels. HDL functionality was determined by monitoring the activities of paraoxonase-1 (PON-1), cholesteryl ester transfer protein (CETP) and lecithin cholesterol acyltransferase (LCAT). Lycopene increased in serum and HDL(2&3) following both lycopene interventions (P<.001, for all), while SAA decreased in serum following the lycopene supplement and in HDL(3) following both lycopene interventions (P<.05 for all). PON-1 activity increased in serum and HDL(2&3) in both lycopene groups (P<.05, for all). Furthermore, the activity of CETP decreased in serum following the lycopene supplement, while the activity of LCAT increased in serum and HDL(3) following both lycopene interventions (P<.05 for all). These results demonstrate that in moderately overweight, middle-aged subjects, increasing lycopene intake leads to changes to HDL(2&3), which we suggest enhanced their antiatherogenic properties. Overall, these results show the heart-protective properties of increased lycopene intake.

AB - The management of overweight subjects by interventions aimed at reducing inflammation is highly desirable. To date, observational studies have identified a link between increased dietary antioxidant intake and reduced cardiovascular morbidity. However, direct trial evidence regarding the ability of antioxidants to influence inflammation is lacking. Therefore, this study examined lycopene's ability to lower systemic and high-density lipoprotein (HDL)-associated inflammation in moderately overweight middle-aged subjects. Serum was collected before and after a 12-week intervention from 54 moderately overweight, middle-aged individuals. Subjects were randomised to one of three groups: control diet (<10 mg lycopene/week), lycopene-rich diet (224-350 mg lycopene/week) and lycopene supplement (70 mg lycopene/week). HDL was subfractionated into HDL(2&3) by rapid ultracentrifugation. Compliance was monitored by assessing lycopene concentration in serum and HDL(2&3). Systemic and HDL-associated inflammation was assessed by measuring serum amyloid A (SAA) levels. HDL functionality was determined by monitoring the activities of paraoxonase-1 (PON-1), cholesteryl ester transfer protein (CETP) and lecithin cholesterol acyltransferase (LCAT). Lycopene increased in serum and HDL(2&3) following both lycopene interventions (P<.001, for all), while SAA decreased in serum following the lycopene supplement and in HDL(3) following both lycopene interventions (P<.05 for all). PON-1 activity increased in serum and HDL(2&3) in both lycopene groups (P<.05, for all). Furthermore, the activity of CETP decreased in serum following the lycopene supplement, while the activity of LCAT increased in serum and HDL(3) following both lycopene interventions (P<.05 for all). These results demonstrate that in moderately overweight, middle-aged subjects, increasing lycopene intake leads to changes to HDL(2&3), which we suggest enhanced their antiatherogenic properties. Overall, these results show the heart-protective properties of increased lycopene intake.

KW - apolipoprotein A-I

KW - aryldialkylphosphatase

KW - carotenoids

KW - cholesterol ester transfer proteins

KW - humans

KW - lipoproteins, HDL

KW - middle aged

KW - overweight

KW - phosphatidylcholine-sterol o-acyltransferase

KW - serum amyloid A protein

KW - lycopene

KW - HDL2&3 functionality

KW - inflammation

KW - serum amyloid A

KW - HDL-associated enzymes

U2 - 10.1016/j.jnutbio.2012.03.015

DO - 10.1016/j.jnutbio.2012.03.015

M3 - Article

C2 - 22819555

VL - 24

SP - 163

EP - 168

JO - The Journal of Nutritional Biochemistry

JF - The Journal of Nutritional Biochemistry

SN - 0955-2863

IS - 1

ER -